Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report third quarter 2011 financial results after the NASDAQ Global Market closes on November 3.  The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the third quarter as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014   MSC , ... patient safety, today announced the appointment of Mary ... With 28 years of experience preparing companies for ... 2013 as Executive Vice President of Corporate Development and ... performance improvement business , as well as corporate strategy ...
(Date:8/27/2014)... LOS ANGELES , Aug. 27, 2014  Lisa ... 30 years this July 4 holiday, thanks to a ... M.D., Ph.D., an internationally renowned clinician-researcher at the University ... is a 55-year-old Peoria, Ariz. ... progressively robs its victims of sight. On June 2, ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3
... A team of Arizona State University researchers will ... aid development of the next generations of lasers and ... in sensing and imaging for an array of defense ... by an Army Research Office grant through the defense ...
... 5 Signum Biosciences, Inc. today announced the appointment of Dr. ... Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue ... , , , ... Shroot brings to Signum an outstanding track record of success in ...
... the study at the Norris Comprehensive Cancer Center of the University ... , ... Inc. (TSX: AEZ; Nasdaq: AEZS ), (the "Company"), ... announced that the National Institutes of Health ("NIH") has awarded Dr. ...
Cached Biology Technology:Looking to leap forward on laser and photodetector technologies 2Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
... States are markedly underestimating the changes needed to mitigate ... change because they work in ,silos, according to pioneering ... Manchester, discovered that the lack of communication between government ... differences over who is responsible for what. He ...
... fibrillation is a cardiac arrhythmia a chronic irregularity ... people in Germany. Although the condition is not acutely ... serious illnesses, such as cardiac insufficiency, stroke and dementia. ... studies, an international team of researchers, led by LMU ...
... as the "world,s aquarium," the marine ecosystems of the ... methods are depleting the sea,s habitats, creating areas that ... story "Threatened Gulf" . But, as Octavio ... Diego will describe during a presentation at the 2010 ...
Cached Biology News:Governments 'misjudging' scale of CO2 emissions 2When the heart gets out of step 2When the heart gets out of step 3Damage to threatened Gulf of California habitats can be reversed 2
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Biology Products: